SCHEMBL20420780

SCHEMBL20420780

COc1ccc2c(-c3ccc(-c4cccc(Cl)c4)s3)cc(=O)oc2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 2/20 0.52
▸ CA9 Q16790 2/20 0.52
▸ HPGD P15428 6/20 0.47
▸ ALDH1A1 P00352 6/20 0.47
▸ KDM4E B2RXH2 4/20 0.47
▸ HSD17B10 Q99714 2/20 0.47
▸ NOD2 Q9HC29 1/20 0.46
▸ MT-CO2 P00403 1/20 0.46
▸ BCHE P06276 1/20 0.46
▸ ALOX5 P09917 1/20 0.46
▸ ACHE P22303 1/20 0.46
▸ RECQL P46063 2/20 0.46
▸ USP2 O75604 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ KCNA3 P22001 2/20 0.45
▸ LMNA P02545 1/20 0.44
▸ CA1 P00915 1/20 0.44
▸ CA2 P00918 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20420776 0.91 HPGD (0.55) CA12CA9HPGDALDH1A1KDM4E
SCHEMBL20420750 0.90 CA1 (0.52) CA12CA9HPGDALDH1A1KDM4E
SCHEMBL20420745 0.84 MAOB (0.55) CA12CA9HPGDALDH1A1KDM4E
SCHEMBL20420754 0.83 CA12 (0.51) CA12CA9HPGDALDH1A1KDM4E
SCHEMBL20420779 0.83 CA12 (0.53) CA12CA9KCNA3CA1TNKS
SCHEMBL20420801 0.82 HPGD (0.51) HPGDALDH1A1KDM4EHSD17B10RECQL
SCHEMBL20420762 0.80 ALDH1A1 (0.51) CA9HPGDALDH1A1KDM4ERECQL
SCHEMBL20420772 0.80 ALDH1A1 (0.49) CA12CA9HPGDALDH1A1KDM4E
SCHEMBL20428335 0.80 APP (0.52) CA12CA9HPGDALDH1A1KDM4E
SCHEMBL20420786 0.79 ALDH1A1 (0.52) HPGDALDH1A1KDM4EHSD17B10NOD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108349959-B 4-substituted coumarin derivative and preparation method and application thereof 成都赜灵生物医药科技有限公司 2021-11-16 — — CN disclosed
US-10544134-B2 4-substituted coumarin derivatives and preparation methods and uses thereof GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD. (CN) 2020-01-28 — — US disclosed
US-10544134-B2 4-substituted coumarin derivatives and preparation methods and uses thereof GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD. (CN) 2020-01-28 — — US disclosed
US-20180282315-A1 4-SUBSTITUTED COUMARIN DERIVATIVES AND PREPARATION METHODS AND USES THEREOF CHENGDU ZENITAR BIOMEDICAL TECHNOLOGY CO., LTD. (CN) 2018-10-04 — — US disclosed
EP-3354648-A1 4-SUBSTITUED COUMARIN DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF Guizhou Bailing Group Pharmaceutical Co., Ltd. (CN) 2018-08-01 — — EP disclosed
EP-3354648-A1 4-SUBSTITUED COUMARIN DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF Guizhou Bailing Group Pharmaceutical Co., Ltd. (CN) 2018-08-01 — — EP disclosed
CN-108349959-A The coumarin derivative and its preparation method and application of 4 substitutions 贵州百灵企业集团制药股份有限公司 2018-07-31 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10544134-B2 4-substituted coumarin derivatives and preparation methods and uses thereof MAP4, TUBA3C, ABCC1 CA12 3561/4885CA9 2723/4885HPGD 2933/4885
US-20180282315-A1 4-SUBSTITUTED COUMARIN DERIVATIVES AND PREPARATION METHODS AND USES THEREOF MAP4, TUBA3C, ABCC1 CA12 3561/4885CA9 2723/4885HPGD 2933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback